At Revitope, with our team of creative and highly engaged scientists and industry veterans, we have engineered next-generation therapeutic T cell engagers that are active only when they bind two ...

Body cells replicate periodically (through mitosis, or cell division), but normal cells respond to their ... replicate even though this tissue doesn't need replacement cells at this time or ...

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

Weill Cornell Medicine researchers have discovered a way ovarian tumors cripple immune cells: by tampering with their ability ...

Programmed Cell Death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies called checkpoint ...

"Researchers have focused on a protein called fatty acid-binding protein 5, or FABP5 ... same problem—Transgelin 2 repression ...

CD19-targeted therapies like CAR-T and T-cell engagers (TCEs) are used for B-cell malignancies, with early success in autoimmune diseases like SLE. However, TCEs face challenges due to ...

overexpressed in normal cells, such as red blood cells and cancer cells. Sino Biological has used the Beacon ® single B cell platform to screen various CD47 antibodies that bind to protein and ...

Unusual variations in the cellular protein factory can skew development, help cancer spread, and more. But ribosome variety ...

Ovarian cancer presents significant challenges due to its tumor microenvironment—a complex network of cells, molecules, and ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...